SOUTH SAN FRANCISCO, Calif., Dec. 8 RigelPharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower,Rigel's chairman and chief executive officer, will participate in a paneldiscussion at the 2008 RBC Capital Marketing Healthcare Conference. The panel,entitled, "New Drugs and Targets for Inflammation and Rheumatology", will takeplace on Wednesday, December 10, 2008 at 10:00 a.m. EST at The Westin TimesSquare Hotel in New York City.
To access the live audio webcast or the subsequent archived recording, logon to http://www.rigel.com. Please connect to Rigel's website several minutesprior to the start of the live webcast to ensure adequate time for anysoftware download that may be necessary.
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers anddevelops novel, small-molecule drugs for the treatment ofinflammatory/autoimmune diseases and cancer, as well as viral and metabolicdiseases. Our pioneering research focuses on intracellular signaling pathwaysand related targets that are critical to disease mechanisms. Rigel'sproductivity has resulted in strategic collaborations with largepharmaceutical partners to develop and market our product candidates. Rigelhas product development programs in inflammatory/autoimmune diseases such asrheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Contact: Ryan Maynard
SOURCE Rigel Pharmaceuticals, Inc.